Cobrabio in manufacturing agreement with ViroMed for VM206RY
International manufacturer of biopharmaceuticals, Cobra Biomanufacturing has signed an agreement with ViroMed Co in Korea to produce VM206RY, a plasmid DNA treatment for tumours expressing Her2/neu (breast, ovarian, pancreatic, and stomach cancers).
International manufacturer of biopharmaceuticals, Cobra Biomanufacturing has signed an agreement with ViroMed Co in Korea to produce VM206RY, a plasmid DNA treatment for tumours expressing Her2/neu (breast, ovarian, pancreatic, and stomach cancers).
Cobrabio will produce ViroMed's Master Cell Bank and GMP-grade VM206RY for clinical trials that will be held in Korea and in the US.
Simon Saxby, chief executive of Cobra Biomanufacturing said: "ViroMed is Cobra's first client in Asia and we are pleased to extend our services to this fast-growing life sciences market."